Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: ALNY stock price vs DGII: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DGII's multiple
Needs DGII P/E.
Implied fair value · at ALNY's multiple
Needs ALNY P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALNY FY 2025 (ended Dec 31, 2025) · DGII FY 2025 (ended Sep 30, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 90% equity / 10% debt · EV / Revenue 10.25x · EV / EBITDA 63.81x
Capital structure 94% equity / 6% debt · EV / Revenue 6.44x · EV / EBITDA 28.58x
ALNY carries the larger enterprise value at $38.07B against $2.77B; DGII trades on the lower EV / Revenue multiple (6.44x vs 10.25x); DGII on the lower EV / EBITDA (28.58x vs 63.81x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
DIGI INTERNATIONAL INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
5.22x
0.25x
Net debt / EBITDA
Leverage against operating earnings
4.13x
1.42x
Cash and equivalents
Liquid reserves on the balance sheet
$1.66B
$21.90M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Moderna, Inc.
ALNY vs MRNA
Sarepta Therapeutics, Inc.
ALNY vs SRPT
VERTEX PHARMACEUTICALS INC / MA
ALNY vs VRTX
BioNTech SE
ALNY vs BNTX
ACADIA PHARMACEUTICALS INC
ALNY vs ACAD
CISCO SYSTEMS, INC.
ALNY vs CSCO
JUNIPER NETWORKS INC
ALNY vs JNPR
QUALCOMM INC/DE
ALNY vs QCOM
INTEL CORP
ALNY vs INTC
VERISIGN INC/CA
ALNY vs VRSN
Match Group, Inc.
ALNY vs MTCH
$4.12B
$159.15M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
